You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
康緣藥業(600557.SH):苓桂術甘顆粒獲批上市
格隆匯 12-29 18:07

格隆匯12月29日丨康緣藥業(600557.SH)公佈,公司於近日收到國家藥品監督管理局簽發的苓桂術甘顆粒《藥品註冊證書》。

苓桂術甘湯為温化水濕的代表方,具有温陽化飲,健脾利濕功效,用於中陽不足之痰飲,自古以來有較多醫案證據作為支撐,而現代又進行了大量的臨牀及實驗研究,其結果為各類醫藥教材所借鑑,業內認可度高。作為中醫常用方劑之一,在慢性心力衰竭、心率失常、冠心病、慢性支氣管炎、非酒精性脂肪肝、眩暈、哮喘、水腫等疾病的治療上被廣泛應用。

為深入發掘中醫藥寶庫精華,推進古代經典名方向新藥轉化,公司與上海中醫藥大學合作研發,依據國家藥監局相關法規和指導原則要求,將苓桂術甘湯研製成苓桂術甘顆粒,是國家藥監局首個批准上市的按古代經典名方目錄管理的中藥複方製劑,將有利於促進古代經典名方在臨牀更廣泛的使用,並有助於提升中醫臨牀服務水平及患者用藥的便捷性。截至公吿披露日,公司對苓桂術甘顆粒項目累計研發投入約922萬元。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account